PAK4 Antibody (B-6): sc-393367

PAK4 Antibody (B-6) is a mouse monoclonal IgG1 antibody that detects PAK4 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PAK4 is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell motility, proliferation, and survival, making PAK4 an important target for understanding cancer progression and metastasis. PAK4 is primarily located in the cytoplasm and translocates to the Golgi apparatus upon activation, where PAK4 interacts with polymerized actin clusters and beta coat proteins, highlighting PAK4′s involvement in cytoskeletal dynamics and intracellular signaling. PAK4′s interaction with GTP-bound CDC42 and ability to phosphorylate downstream substrates, such as MEK kinase, underscore PAK4′s significance in the JNK signaling pathway, which is vital for cellular responses to stress and growth factors. The gene encoding PAK4 is located on human chromosome 19, and PAK4 expression is notably high in tissues such as the prostate, testis, and colon, indicating PAK4′s potential role in tissue-specific functions and disease states. Anti-PAK4 antibody (B-6) is an essential tool for researchers investigating the molecular mechanisms underlying PAK4′s function and implications in various biological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PAK4 Antibody (B-6) References:

1. Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis.  |  Wang, C., et al. 2014. Oncogene. 33: 3473-84. PMID: 23934187
2. PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion.  |  Dart, AE., et al. 2015. J Cell Biol. 211: 863-79. PMID: 26598620
3. Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review.  |  Wang, H., et al. 2021. Expert Opin Ther Pat. 31: 977-987. PMID: 34369844
4. PAK4 as a cancer immune-evasion target.  |  Gajewski, TF. and Fessler, J. 2020. Nat Cancer. 1: 18-19. PMID: 35121838
5. P21-Activated Kinase 4 Pak4 Maintains Embryonic Stem Cell Pluripotency via Akt Activation.  |  Cheng, F., et al. 2022. Stem Cells. 40: 892-905. PMID: 35896382
6. PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration.  |  Su, S., et al. 2023. Cancer Lett. 555: 216034. PMID: 36509363
7. Expression Patterns of PAK4 and PHF8 Are Associated with the Survival of Gallbladder Carcinoma Patients.  |  Ahn, AR., et al. 2023. Diagnostics (Basel). 13: PMID: 36980457
8. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.  |  Khan, HY., et al. 2023. Mol Cancer Ther. 22: 1422-1433. PMID: 37703579
9. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response.  |  Xu, S., et al. 2024. EBioMedicine. 104: 105162. PMID: 38810561
10. Inhibition of NAMPT by PAK4 Inhibitors.  |  Wang, Y. and Minden, A. 2024. Int J Mol Sci. 25: PMID: 39337621

The preferred PAK4 antibody is PAK4 Antibody (B-3): sc-390507.